

Enduring Learner Notification

Ocular Immunology and Uveitis Foundation
2024 Ocular Inflammatory Disease Crash Course
Date of CE Release: 09-22-2024
Date of CE Expiration: 09-22-2025
Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Ocular Immunology and Uveitis Foundation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163

Physicians

Amedco LLC designates this material for a maximum of 6.75 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE

This activity, COPE Activity Number 129265, is accredited by COPE for continuing education for optometrists.

Objectives - After Attending This Program You Should Be Able To

1. Assess various forms of anterior and posterior ocular inflammatory disease and Identify preferred practice patterns for monitoring and treating ocular inflammatory diseases.
2. Consider taking early action in management upon recognition of these diseases and how to take a multidisciplinary approach to help avoid permanent complications caused by delay in treatment.
3. Understand emerging therapies for these diseases and how to navigate insurance.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Peter Chang	Mallinckrodt, Bausch & Lomb, Alcon:Speakers Bureau X4 pharmaceuticals, Genentech:Consultant Ocugen, Alimera Sciences:Scientific/Medical Advisory Board Member
David Chu,MD	Aldeyra, Bausch and Lomb, Kriya, Santen and Théa:Consultant Mallinckrodt :Speakers Bureau None:Other Financial or Material Support Mallinckrodt:Research Grant Overall Principal Investigator
Christopher Compton	NA
Frances foster	NA
Stephen Foster	Eyegate Pharma:Stock Shareholder Cartesian Therapeutics :Consultant
Wendy Huang	NA
Melis Kabaalioglu Guner	NA
Rajiv Shah	Allergan, Amgen, Regeneron, Mallinckrodt:Speakers Bureau Genetech:Research Grant Site Principal Investigator Bausch Lomb:Scientific/Medical Advisory Board Member
Joern Soltau	CVS Caremark:Consultant
Wei Wang	NA
Alison Justus	NA
Ava Krmpotich	NA

How to Get Your Certificate

1. Go to oiuf.cmecertificateonline.com
2. Click on the **2024 Ocular Inflammatory Disease Crash Course** link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com